Alessandra Fabi
Università Campus Bio-Medico
PathologyOncologyMetastatic breast cancerBreast cancerMedicine
What is this?
Publications 310
#1Roberta CaputoH-Index: 5
#2Marina CazzanigaH-Index: 20
Last. Domenico BilanciaH-Index: 14
view all 18 authors...
#1Alessandra FabiH-Index: 30
Last. C. RipamontiH-Index: 4
view all 9 authors...
INTRODUCTION: Narrative medicine makes explicit the experience of disease and enhances the subjective view in the cure. In addition, the narrative approach involves personal experience and emotional resonances of the health care professional leading him to redefine the values in terms of health and disease. The IMPERO study aims to explore the personal "life experience" of health care professionals involved in studies exploring a new methodological clinical approach: the use of a digital narrati...
#1Nicla La VerdeH-Index: 11
#2Giovanna DamiaH-Index: 28
Last. Paolo PedrazzoliH-Index: 29
view all 22 authors...
BACKGROUND: Metastatic breast cancer (MBC) is an incurable disease and its treatment focuses mainly on prolonging patients (pts) survival and improving their quality of life. As a consequence, management of treatment related adverse events (AE) is very important. Eribulin (E) is a microtubule inhibitor that has shown to increase overall survival in pre-treated MBC pts. Its most common AEs are asthenia, neutropenia and peripheral neuropathy (N). PATIENTS AND METHODS: PAINTER (Clinical trial regis...
#1Giorgio Mustacchi (UniTS: University of Trieste)H-Index: 15
#2Alessandra BeanoH-Index: 4
Last. Laura BiganzoliH-Index: 33
view all 20 authors...
Background: TNBC shows a very bad prognosis: median time to relapse is 18 months and median overall survival (OS) is less than 24 months. Methods: AMBRA is a longitudinal cohort study, describing the choice of 1st- and subsequent treatments in HER2-ve MBC pts in the years 2012-2015. The present analysis is focused on TNBC pts (127 out of 879 evaluable; 14.4%) and CHT strategies, overall and according to adj treatment. Kaplan Meyer probability of survival from primary (DFS), 1st(PFS1) and 2nd(PFS...
#1Alessandra FabiH-Index: 30
view all 23 authors...
Background: Several randomized clinical trials clearly demonstrated that adding palbociclib (P) to endocrine therapies (ET), such as letrozole (LT) or fulvestrant (FLV), significantly improves outcome both in first-line/endocrine sensitive and second-line/endocrine resistant hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2) metastatic breast cancer (MBC) patients (pts). The aims of the present study were to assess efficacy, activity and toxicity of P combi...
#1Marina CazzanigaH-Index: 20
#2C. VerusioH-Index: 9
view all 51 authors...
#1Alessandra FabiH-Index: 30
#2Gaetano LanzettaH-Index: 19
Last. Patrizia PuglieseH-Index: 7
view all 15 authors...
Abstract In recent years, we have witnessed a growing interest in the prevention of the loss of reproductive efficacy in young women as a result of cancer or its treatments. Indeed, recent studies have shown that loss of fertility impacts deeply on young women and sometimes may be even more stressful than the cancer diagnosis itself. In fact, the risk of treatment-associated infertility and premature menopause is a major concern for patients. Nevertheless, the approach to fertility preservation ...
#1Benedetta ConteH-Index: 3
#2Alessandra FabiH-Index: 30
Last. Lucia Del MastroH-Index: 24
view all 21 authors...
Abstract Background T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy...